Patterns of chronic lymphocytic leukemia growth identified
(Dana-Farber Cancer Institute) In patients with chronic lymphocytic leukemia, the rate of disease growth is apt to follow one of three trajectories: relentlessly upward, steadily level, or something in between, scientists at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the University of Washington report in a new study published in Nature. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2019 Category: International Medicine & Public Health Source Type: news
Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients
(University of Texas M. D. Anderson Cancer Center) Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2019 Category: Cancer & Oncology Source Type: news
FDA Okays Venclexta Plus Gazyva for Previously Untreated Chronic Lymphocytic Leukaemia FDA Okays Venclexta Plus Gazyva for Previously Untreated Chronic Lymphocytic Leukaemia
Roche said on Thursday that the U.S. Food and Drug Administration had approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 17, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FDA Approves Venetoclax for Chronic Lymphocytic Leukemia
In randomized trial, drug demonstrated statistically significant improvement in progression - free survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 17, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news
FDA Approves Venetoclax for Chronic, Small Lymphocytic Leukemia
THURSDAY, May 16, 2019 -- Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. Food and Drug Administration announced yesterday.
Data from CLL14, a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 16, 2019 Category: Pharmaceuticals Source Type: news
Roche: FDA approves drug combo Venclexta plus Gazyva for previously untreated chronic lymphocytic leukemia
Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Roche today announced that the US Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). (Source: Roche Investor Update)
Source: Roche Investor Update - May 16, 2019 Category: Pharmaceuticals Source Type: news
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Roche today announced that the US Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). (Source: Roche Media News)
Source: Roche Media News - May 16, 2019 Category: Pharmaceuticals Source Type: news
AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients
NORTH CHICAGO, Ill., May 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2019 Category: Drugs & Pharmacology Source Type: news
Researchers pinpoint why lymphoma patients may become resistant to specific therapy
(H. Lee Moffitt Cancer Center& Research Institute) Researchers from Moffitt Cancer Center and Dana-Farber Cancer Institute have discovered a mechanism of drug resistance to Venetoclax ® , also known as ABT-199, a BCL-2 targeting drug commonly used to treat chronic lymphocytic leukemia and acute myeloid leukemia. Their findings, published in the journal Cancer Cell, also suggest a possible co-treatment strategy to overcome this resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 15, 2019 Category: Cancer & Oncology Source Type: news
Medical trials at Aurora Research Institute uncover lifesaving news for leukemia patients
A prolonged life and fewer side effects are among the benefits for leukemia patients on a specific drug regimen, according to two new clinical trials.
The breakthrough findings are expected to immediately change the treatment for patients with leukemia.
Both trials Aurora Research Institute studied the anticancer drug called ibrutinib for treating chronic lymphocytic leukemia (CLL).
“CLL is the most common leukemia in adults in Western count ries,” said Dr. Rubina Qamar, the principal investigator… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 29, 2019 Category: Biotechnology Authors: Advocate Aurora Health Source Type: news
Medical trials at Aurora Research Institute uncover lifesaving news for leukemia patients
A prolonged life and fewer side effects are among the benefits for leukemia patients on a specific drug regimen, according to two new clinical trials.
The breakthrough findings are expected to immediately change the treatment for patients with leukemia.
Both trials Aurora Research Institute studied the anticancer drug called ibrutinib for treating chronic lymphocytic leukemia (CLL).
“CLL is the most common leukemia in adults in Western count ries,” said Dr. Rubina Qamar, the principal investigator… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 29, 2019 Category: American Health Authors: Advocate Aurora Health Source Type: news
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - March 7, 2019 Category: Pharmaceuticals Source Type: news
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Media News)
Source: Roche Media News - March 7, 2019 Category: Pharmaceuticals Source Type: news
FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Na ïve Patients with Chronic Lymphocytic Leukemia
HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with obinutuzumab in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 28, 2019 Category: Drugs & Pharmacology Source Type: news
